Cargando…

Blood and CSF Biomarker Dynamics in Multiple Sclerosis: Implications for Data Interpretation

Background. Disability in multiple sclerosis (MS) is related to neuroaxonal degeneration. A reliable blood biomarker for neuroaxonal degeneration is needed. Objectives. To explore the relationship between cerebrospinal fluid (CSF) and serum concentrations of a protein biomarker for neuroaxonal degen...

Descripción completa

Detalles Bibliográficos
Autores principales: Eikelenboom, M. J., Uitdehaag, B. M. J., Petzold, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195856/
https://www.ncbi.nlm.nih.gov/pubmed/22096644
http://dx.doi.org/10.1155/2011/823176
_version_ 1782214174041964544
author Eikelenboom, M. J.
Uitdehaag, B. M. J.
Petzold, A.
author_facet Eikelenboom, M. J.
Uitdehaag, B. M. J.
Petzold, A.
author_sort Eikelenboom, M. J.
collection PubMed
description Background. Disability in multiple sclerosis (MS) is related to neuroaxonal degeneration. A reliable blood biomarker for neuroaxonal degeneration is needed. Objectives. To explore the relationship between cerebrospinal fluid (CSF) and serum concentrations of a protein biomarker for neuroaxonal degeneration, the neurofilaments heavy chain (NfH). Methods. An exploratory cross-sectional (n = 51) and longitudinal (n = 34) study on cerebrospinal fluid (CSF) and serum NfH phosphoform levels in patients with MS. The expanded disability status scale (EDSS), CSF, and serum levels of NfH-SMI34 and NfH-SMI35 were quantified at baseline. Disability progression was assessed at 3-year followup. Results. At baseline, patients with primary progressive MS (PPMS, EDSS 6) and secondary progressive MS (SPMS, EDSS 6) were more disabled compared to patients with relapsing remitting MS (RRMS, EDSS 2, P < .0001). Serum and CSF NfH phosphoform levels were not correlated. Baseline serum levels of the NfH-SMI34 were significantly (P < .05) higher in patients with PPMS (2.05 ng/mL) compared to SPMS (0.03 ng/mL) and RRMS (1.56 ng/mL). In SPMS higher serum than CSF NfH-SMI34 levels predicted disability progression from baseline (ΔEDSS 2, P < .05). In RRMS higher CSF than serum NfH-SMI35 levels predicted disability progression (ΔEDSS 2, P < .05). Conclusion. Serum and CSF NfH-SMI34 and NfH-SMI35 levels did not correlate with each other in MS. The quantitative relationship of CSF and serum NfH levels suggests that neuroaxonal degeneration of the central nervous system is the likely cause for disability progression in RRMS. In more severely disabled patients with PP/SPMS, subtle pathology of the peripheral nervous system cannot be excluded as an alternative source for blood NfH levels. Therefore, the interpretation of blood protein biomarker data in diseases of the central nervous system (CNS) should consider the possibility that pathology of the peripheral nervous system (PNS) may influence the results.
format Online
Article
Text
id pubmed-3195856
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-31958562011-11-17 Blood and CSF Biomarker Dynamics in Multiple Sclerosis: Implications for Data Interpretation Eikelenboom, M. J. Uitdehaag, B. M. J. Petzold, A. Mult Scler Int Research Article Background. Disability in multiple sclerosis (MS) is related to neuroaxonal degeneration. A reliable blood biomarker for neuroaxonal degeneration is needed. Objectives. To explore the relationship between cerebrospinal fluid (CSF) and serum concentrations of a protein biomarker for neuroaxonal degeneration, the neurofilaments heavy chain (NfH). Methods. An exploratory cross-sectional (n = 51) and longitudinal (n = 34) study on cerebrospinal fluid (CSF) and serum NfH phosphoform levels in patients with MS. The expanded disability status scale (EDSS), CSF, and serum levels of NfH-SMI34 and NfH-SMI35 were quantified at baseline. Disability progression was assessed at 3-year followup. Results. At baseline, patients with primary progressive MS (PPMS, EDSS 6) and secondary progressive MS (SPMS, EDSS 6) were more disabled compared to patients with relapsing remitting MS (RRMS, EDSS 2, P < .0001). Serum and CSF NfH phosphoform levels were not correlated. Baseline serum levels of the NfH-SMI34 were significantly (P < .05) higher in patients with PPMS (2.05 ng/mL) compared to SPMS (0.03 ng/mL) and RRMS (1.56 ng/mL). In SPMS higher serum than CSF NfH-SMI34 levels predicted disability progression from baseline (ΔEDSS 2, P < .05). In RRMS higher CSF than serum NfH-SMI35 levels predicted disability progression (ΔEDSS 2, P < .05). Conclusion. Serum and CSF NfH-SMI34 and NfH-SMI35 levels did not correlate with each other in MS. The quantitative relationship of CSF and serum NfH levels suggests that neuroaxonal degeneration of the central nervous system is the likely cause for disability progression in RRMS. In more severely disabled patients with PP/SPMS, subtle pathology of the peripheral nervous system cannot be excluded as an alternative source for blood NfH levels. Therefore, the interpretation of blood protein biomarker data in diseases of the central nervous system (CNS) should consider the possibility that pathology of the peripheral nervous system (PNS) may influence the results. Hindawi Publishing Corporation 2011 2011-04-14 /pmc/articles/PMC3195856/ /pubmed/22096644 http://dx.doi.org/10.1155/2011/823176 Text en Copyright © 2011 M. J. Eikelenboom et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Eikelenboom, M. J.
Uitdehaag, B. M. J.
Petzold, A.
Blood and CSF Biomarker Dynamics in Multiple Sclerosis: Implications for Data Interpretation
title Blood and CSF Biomarker Dynamics in Multiple Sclerosis: Implications for Data Interpretation
title_full Blood and CSF Biomarker Dynamics in Multiple Sclerosis: Implications for Data Interpretation
title_fullStr Blood and CSF Biomarker Dynamics in Multiple Sclerosis: Implications for Data Interpretation
title_full_unstemmed Blood and CSF Biomarker Dynamics in Multiple Sclerosis: Implications for Data Interpretation
title_short Blood and CSF Biomarker Dynamics in Multiple Sclerosis: Implications for Data Interpretation
title_sort blood and csf biomarker dynamics in multiple sclerosis: implications for data interpretation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195856/
https://www.ncbi.nlm.nih.gov/pubmed/22096644
http://dx.doi.org/10.1155/2011/823176
work_keys_str_mv AT eikelenboommj bloodandcsfbiomarkerdynamicsinmultiplesclerosisimplicationsfordatainterpretation
AT uitdehaagbmj bloodandcsfbiomarkerdynamicsinmultiplesclerosisimplicationsfordatainterpretation
AT petzolda bloodandcsfbiomarkerdynamicsinmultiplesclerosisimplicationsfordatainterpretation